ValiRx PLC Statement re broker (5358G)
02 March 2018 - 10:01PM
UK Regulatory
TIDMVAL
RNS Number : 5358G
ValiRx PLC
02 March 2018
VALIRX PLC
("ValiRx", the "Company" or the "Group")
Statement re broker
The Company notes the announcement today regarding Beaufort
Securities Limited ("BSL") and Beaufort Asset Clearing Services
Limited ("BACSL") being placed into insolvency and that the
Financial Conduct Authority (the "FCA") has imposed requirements on
BSL and BACSL to cease all regulatory activity.
BSL is the broker to the Company pursuant to the AIM Rules for
Companies (the "AIM Rules"). As a result of the requirements
imposed by the FCA, BSL will no longer be able to provide broking
services to the Company in accordance with the AIM Rules.
The Company is seeking to appoint a new broker as soon as
possible and a further announcement will be made when this
appointment is made.
*** ENDS ***
For more information, please contact:
ValiRx plc Tel: +44 (0) 20
3008 4416
www.valirx.com
Dr Satu Vainikka, Chief Executive Tel: +44 (0) 20
3008 4416
Tarquin Edwards, Head of Communications. Tel: +44 (0) 7879
458 364
tarquin.edwards@valirx.com
Cairn Financial Advisers LLP Tel: +44 (0) 20
(Nominated Adviser) 7213 0880
Liam Murray/Jo Turner/Richard
Nash
Notes for Editors
About ValiRx
ValiRx is a biotechnology oncology focused company specialising
in developing novel treatments for cancer and associated
biomarkers. It aims to make a significant contribution in
"precision" medicine and science, namely to engineer a breakthrough
into human health and well-being, through the early detection of
cancer and its therapeutic intervention.
The Company's business model focuses on out-licensing
therapeutic candidates early in the development process. By aiming
for early-stage value creation, the company reduces risk
considerably while increasing the potential for realising value.
The group is already in licensing discussions with major players in
the oncology field.
ValiRx's two classes of drugs in development, which each have
the potential for meeting hitherto unmet medical needs by existing
methods, have worldwide patent filings and agreed commercial
rights. They originate or derive from World class institutions,
such as Cancer Research UK and Imperial College.
Until recently, cancer treatments relied on non-specific agents,
such as chemotherapy. With the development of target-based agents,
primed to attack cancer cells only, less toxic and more effective
treatments are now possible. New drugs in this group-such as those
in ValiRx's pipeline-promise to greatly improve outcomes for cancer
patients.
The Company listed on the AIM Market of the London Stock
Exchange in October 2006 and trades under the ticker symbol:
VAL
This information is provided by RNS
The company news service from the London Stock Exchange
END
APPEAFDAEEEPEFF
(END) Dow Jones Newswires
March 02, 2018 06:01 ET (11:01 GMT)
Valirx (LSE:VAL)
Historical Stock Chart
From Apr 2024 to May 2024
Valirx (LSE:VAL)
Historical Stock Chart
From May 2023 to May 2024